Register
|
Login
The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
NEWS
CONFERENCES
VIDEOS
Case-Based Peer Perspectives
Expert Perspective Virtual Tumor Board
Interviews
Investigator Perspectives
Precision Medicine
PUBLICATIONS
Evolving Paradigms
Targeted Therapies in Oncology
The Journal of Targeted Therapies in Cancer
ONCAlert | Upfront Therapy for mRCC
Specialties >>
AML
Bladder Cancer
Breast Cancer
CLL
Colorectal Cancer
DLBCL
EGFR+ Lung Cancer
Follicular Lymphoma
GI Cancers
Gynecologic Cancers
HCC
Head & Neck Cancers
Hematology
HER2-Negative Breast Cancer
Immunotherapy
Liquid Biopsies
Lung Cancer
Lymphomas
Mantle Cell Lymphoma
Melanoma
MPNs
Multiple Myeloma
Ovarian Cancer
Prostate Cancer
Renal Cell Carcinoma
Skin Cancers
Thyroid Cancers
More >>
Partners >>
Dialogues in Diagnostics
Differential Diagnosis
Case-Based Peer Perspectives
Email Sign-Up
Targeted Therapies in Oncology
November 2013
Clinical Articles
SABCS Preview: Prevention, Screening, and Neoadjuvant Therapies
Model Emerges for Targeting Oncogenes in NSCLC
Additional OS and PFS Benefits With Aflibercept in Post-Hoc VELOUR Analysis
TRINOVA-1 Trial: Promise for Trebananib in Ovarian Cancer
Biomarkers at 12 Weeks Predict Prognosis in mCRPC at 2 Years
JTT Articles
Participating Practices Commend CMS for OCM Changes
The Role of Liquid Biopsy in NSCLC Continues to Emerge
Rare Incidence of ICI-Related Hepatotoxicity Frequently Ends in Treatment Discontinuation
>> View Peer-Reviewed Articles
Most Popular
FDA Grants Fast Track and Orphan Drug Designations to Novel Agent Targeting P53 in MDS
Levy Works Through Therapy Options in Patients With NSCLC Who Lack a Driver Mutation
Immunotherapy and TKI Combinations Are Emerging as Standard of Care in Advanced RCC
TMB Shows Promise as Biomarker for Durvalumab Activity in NSCLC
